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Background: The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Although C-HIV
predominates in developing regions of the world such as Southern Africa and Central Asia, C-HIV is also spreading
rapidly in countries with more developed economies and health care systems, whose populations are more likely to
have access to wider treatment options, including the CCR5 antagonist maraviroc (MVC). The ability to reliably
determine C-HIV coreceptor usage is therefore becoming increasingly more important. In silico V3 sequence based
coreceptor usage prediction algorithms are a relatively rapid and cost effective method for determining HIV-1
coreceptor specificity. In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and
used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor
usage prediction algorithm.
Results: We characterized every phenotypically-verified C-HIV gp120 V3 sequence available in the Los Alamos HIV
Database. Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences
have significantly greater amino acid variability, increased net charge, increased amino acid length, increased
frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation
sites. Based on these findings, we developed a novel C-HIV specific coreceptor usage prediction algorithm
(CoRSeqV3-C), which we show has superior sensitivity for determining CXCR4 usage by C-HIV strains compared to all
other available algorithms and prediction rules, including Geno2pheno[coreceptor] and WebPSSMSINSI-C, which has
been designed specifically for C-HIV.
Conclusions: CoRSeqV3-C is now openly available for public use at www.burnet.edu.au/coreceptor. Our results show
that CoRSeqV3-C is the most sensitive V3 sequence based algorithm presently available for predicting CXCR4 usage
of C-HIV strains, without compromising specificity. CoRSeqV3-C may be potentially useful for assisting clinicians to
decide the best treatment options for patients with C-HIV infection, and will be helpful for basic studies of C-HIV
pathogenesis.
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Human immunodeficiency virus type 1 (HIV-1) gains
entry into immune cells by binding to CD4 and one of
two coreceptors, CCR5 or CXCR4 [1-4]. HIV-1
phenotypes are defined by the ability of HIV-1 to use
CCR5 (R5), CXCR4 (X4) or both coreceptors (R5X4) for
entry [5]. Transmission and establishment of HIV-1
infections is typically associated with R5 viruses. However,
in 40-50% of individuals infected with subtype B HIV-1
(B-HIV), R5X4 and/or X4 viruses (collectively referred to
hereafter as CXCR4-using viruses) emerge during disease
progression [6,7]. The emergence of CXCR4-using viruses
is associated with rapid CD4+ T-cell decline and
accelerated onset of AIDS [8]. In contrast, individuals
infected with subtype C HIV-1 (C-HIV) frequently harbor
R5 viruses throughout all stages of disease [9] (reviewed in
[10,11]). However, recent studies are reporting increased
incidence of CXCR4-using C-HIV strains emerging at late
stages of infection (up to 52%) [12-15], which may be
associated with exposure to antiretroviral therapies (ART).
Importantly, C-HIV infections constitute the majority of
HIV-1 infections worldwide and are responsible for more
than 95% of HIV-1 infections in Southern Africa, Central
Asia and parts of South-East Asia, which are regions of
the world where the HIV-1 pandemic is at its worst [11].
Furthermore, C-HIV is now spreading rapidly in more
developed nations such as Brazil and neighboring
countries [16].
The CCR5 antagonist maraviroc (MVC) is presently used
as an antiretroviral (ARV) for treatment of HIV-1 infected
subjects who have no detectable CXCR4-using virus in
their plasma [17-19]. Thus, the ability to phenotypically
characterize coreceptor usage of circulating HIV-1 strains
has become clinically important. Currently, the gold
standard for determining viral coreceptor usage is a cell
entry assay with infectious viruses pseudotyped with
patient-derived envelopes [20]. However, this method is
expensive, labor intensive and time consuming and
therefore, impractical in resource constrained regions
where C-HIV predominates. Consequently, sequence
based in silico predictive algorithms capable of
predicting viral coreceptor usage have been developed,
principally for B-HIV variants, offering a rapid, simplistic
and inexpensive alternative to cell based entry assays.
Studies have shown that the major determinants of HIV-
1 CCR5 and/or CXCR4 usage lie within the third variable
loop (V3) of the viral surface envelope glycoprotein, gp120
[21-25]. Current coreceptor usage prediction algorithms
exploit these V3 sequence characteristics in order to predict
coreceptor specificity. Studies assessing the accuracy of cur-
rently available coreceptor usage prediction algorithms have
shown limited success in regards to correctly predicting
C-HIV coreceptor usage [26-31]. These algorithms
will need significant improvements in order for MVCand other future CCR5 antagonists to become accessible
for the vast majority of subjects with C-HIV infection. In
this study, we aimed to develop and validate a novel, user
friendly and highly specific C-HIV specific coreceptor
usage prediction algorithm.
Results
C-HIV V3 sequence characteristics associated with
coreceptor usage
In this study we analyzed all the phenotypically cha-
racterized patient-derived C-HIV V3 sequences
currently available in the Los Alamos HIV Database in
order to identify potential V3 sequence characteristics
capable of differentiating CXCR4-using from R5 HIV-C
Envs. We selected one representative CXCR4-using and/
or R5 V3 sequence per subject in order to avoid biasing
the results by the resampling of highly related sequences.
In total, we assembled 69 unique CXCR4-using and 473
unique R5 C-HIV V3 sequences.
CXCR4-using C-HIV V3 sequences were found to be
significantly longer (range 32–37 amino acids) than the R5
C-HIV V3 sequences (range 32–35 amino acids; p<0.0001
by a Mann Whitney U test) (Figure 1A). Also, the net
charge of CXCR4-using V3 sequences (range 3–10) was
significantly higher than that of R5 V3 sequences (range
0–6; p<0.0001 by a Mann Whitney U test) (Figure 1C).
Interestingly, the majority of CXCR4-using V3 sequences
had a net charge of ≥6 (Figure 1D). The largely non-
overlapping pattern of CXCR4-using and R5 V3 sequences
suggests that a charge cutoff of ≥6 could be used to predict
CXCR4-usage. Indeed, the V3 net charge of CXCR4-using
C-HIV V3 sequences was significantly greater than that of
the R5 C-HIV V3 sequences when a cutoff of ≥6 was
considered (p<0.0001 by a Mann Whitney U test). In con-
trast, the significant overlap pattern between CXCR4-using
and R5 V3 sequences with a net amino acid length of 35
(Figure 1B) suggests that V3 length may not be a character-
istic sensitive enough to predict coreceptor usage of most
C-HIV strains. However, a cutoff length of ≥36 amino acids
could be used to predict some CXCR4-using C-HIV V3
sequences. Unlike previous studies, we found no asso-
ciation between coreceptor usage and V3 sequence
hydrophobicity using the Kyte Doolittle hydrophobicity
scale (data not shown) [14,29,32-35].
We next produced an entropy plot to more precisely
determine patterns of V3 variability between R5 and
CXCR4-using C-HIV V3 sequences (Figure 2). Higher
entropy values indicate greater variability at specific sites
within V3. The CXCR4-using V3 sequences displayed
greater overall variability than the R5 V3 sequences.
Notably, the residues within the predicted N-glycosylation
site (PNGS) at amino acid positions 6–8 were more
conserved among R5 V3 sequences than CXCR4-using V3
sequences (Figure 2). Consistent with this observation, R5
Figure 1 V3 length and charge alterations associated with C-HIV coreceptor usage. (A, B), A comparison of V3 amino acid lengths
segregating CXCR4-using from R5 C-HIV strains. (C, D), A comparison of V3 charge alterations segregating CXCR4-using from R5 C-HIV strains.
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using V3 sequences (p<0.0001 by a Mann Whitney U test);
20.3% of CXCR4-using V3 sequences lacked a PNGS at this
motif, compared to only 2.5% of R5 V3 sequences
(p=0.0002 by Fisher’s exact test). Residues 15, 16 and 17,
located within the V3 crown motif, also showed greater
variability in CXCR4-using V3 sequences compared with
R5 V3 sequences (Figure 2). In fact, an alteration of at least
one substitution within the V3 crown motif was sig-
nificantly more frequent in CXCR4-using C-HIV V3Figure 2 Entropy plot comparing V3 sequence variability between CX
site, positions 1, 11, 25 and 35, the position of the two amino acid insertion
regions of specific interest, where there is variability within CXCR4-using V3sequences (71%) than in R5 C-HIV V3 sequences
(3.2%) (p<0.0001 by Fisher’s exact test). Furthermore,
a two amino acid insertion immediately upstream of
the V3 crown (Figure 2) was frequently present in
CXCR4-using V3 sequences (42%), yet was never
observed in R5 V3 sequences (p<0.0001 by Fisher’s
exact test). Using mutagenesis studies, we recently showed
that either a V3 crown substitution or a proximal two
amino acid insertion were important for CXCR4-usage of
C-HIV, individually conferring R5X4 phenotypes, andCR4-using and R5 C-HIV Envs. The potential N-linked glycosylation
, and the V3 GPGQ crown motif are highlighted. Boxes illustrate
sequences but little or no variability within R5 V3 sequences.
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together (M.R. Jakobsen, K. Cashin and P.R. Gorry,
unpublished data). Notably, position 25 showed extensive
variability in both R5 and CXCR4-using C-HIV V3
sequences (Figure 2).
Next we determined the type and frequency of amino
acids at individual V3 positions, and compared the
amino acid frequencies of CXCR4-using and R5 V3
sequences. Table 1 displays the amino acid alterations
within V3 that either; (i) only occur in CXCR4-using or
R5 V3 sequences, or (ii) exhibit variability that is signifi-
cantly different between CXCR4-using and R5 V3
sequences, and thus may potentially be able to help
discriminate CXCR4-using from R5 C-HIV viruses. We
next assessed all of the amino acid alterations shown in
Table 1 for their ability to increase the sensitivity of
detecting CXCR4-using C-HIV viruses when tested in
novel prototype coreceptor usage prediction algorithms.
These analyses showed that the presence of Glu10, Ile11,
Asn11, a gap at position 23, Thr25, a gap at position 25,
or Glu32 or Phe34 (Table 1) could all individually contri-
bute to increasing the sensitivity and/or specificity of
detecting CXCR4-using C-HIV variants (Additional file 1).
Interestingly, factoring in the presence or absence of aTable 1 V3 amino acid alterations associated with C-HIV core
Mutation a
Phenotype Fisher’s exact
test (p value)CCR5 usage CXCR4 usage
Asn6Tyr 0 4.3 ns
Asn7Lys 0 4.3 ns
Thr8Ile 0.2 7.2 0.014
Arg9Ile 0 5.8 0.0289
Lys10Glu 4.4 0 ns
Ser11Arg 0.2 15.9 <0.0001
Ser11Asn 0 4.3 ns
Ser11His 0 2.9 ns
Ser11Ile 0 2.9 ns
Ser11Lys 0 1.4 ns
Ile12Lys 0 2.9 ns
Arg13Asn 0 2.9 ns
Arg13- 0.4 8.7 0.0067
Ile14Leu 0.6 10.1 0.0015
Ile14Thr 0 4.3 ns
13-14 insertion 0 40.4 <0.0001
Pro16Arg 0 37.7 <0.0001
Pro16Gln 0 4.3 ns
Gly17Arg 0.4 8.7 0.0067
a Amino acid numbering is based on the consensus C-HIV V3 sequence.
Values are percentages of R5 or CXCR4-using C-HIV V3 sequences.
For these analyses, 69 unique CXCR4-using and 473 unique R5 C-HIV V3 sequences
ns, not significant; -, deleted sequence.PNGS at amino acid positions 6–8 did not improve
sensitivity or specificity (data not shown), despite
being a significant parameter for distinguishing R5
and CXCR4-using sequences.
Other Env sequence characteristics may also distinguish
CXCR4-using C-HIV strains from R5 C-HIV strains
We also performed a similar analysis of gp41 and all
regions of gp120 outside of V3. Sequence characteristics
that were significantly different between R5 and
CXCR4-using C-HIV Envs included net amino acid
charge in the V1 region (p=0.0306 by a Mann Whitney U
test), V1 length (p=0.0415 by a Mann Whitney U Test), the
number of PNGS within V1 (p=0.0363 by a Mann Whitney
U Test), and length of the V4 region (p<0.0001 by a Mann
Whitney U Test). These findings suggest that regions out-
side of the V3 loop may also be involved in determining
coreceptor usage of C-HIV strains, and therefore could be
used to predict coreceptor specificity. However, the
limiting number of phenotypically characterised CXCR4-
using C-HIV sequences containing regions other than V3
(n<40) may limit the significance of these findings, and also
the practicality of including these characteristics in new
C-HIV coreceptor usage prediction algorithms.ceptor usage
Mutation
Phenotype Fisher’s exact
test (p value)CCR5 usage CXCR4 usage
Gln18Arg 1.1 20.3 <0.0001
Gln18His 0.4 13 0.0002
Gln18Lys 0 2.9 ns
Phe20Val 0 7.2 0.0068
Phe20Trp 0 2.9 ns
Thr23- 2.3 0 ns
Thr23Arg 0 5.8 0.0289
Gly24Lys 1.3 13 0.0013
Asp25Arg 0.2 10.1 0.0015
Asp25Lys 0.6 17.4 <0.0001
Asp25Thr 0 7.2 0.0068
Asp25His 0 1.4 ns
Asp25- 2.5 4.3 ns
Ile27Arg 0 7.2 0.0068
Ile27Asn 0 2.9 ns
Gly28Lys 0 2.9 ns
Ile30Val 0 4.3 ns
Gln32Glu 8 0 0.0068
His34Phe 0 7.2 0.0068
were included.
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prediction algorithm
Next we developed a C-HIV specific V3 sequence based
coreceptor usage prediction algorithm, founded princi-
pally on the V3 characteristics that we showed in the
preceding studies could help distinguish CXCR4-using
from R5 C-HIV viruses (CoRSeqV3-C). When a query V3
sequence is submitted to CoRSeqV3-C, which is now
hosted at www.burnet.edu.au/coreceptor and presently
available for use as a research tool, the sequence is aligned
against the HXB2 V3 sequence, and a series of questions
are addressed (Figure 3). For the purpose of sequence
orientation and amino acid number assignment, HXB2 is
the most practical reference sequence because, unlike the
C-HIV consensus sequence, it contains the same number
of amino acids as many CXCR4-using C-HIV Envs. First,
the query sequence is assessed for the presence of amino
acid alterations that occur exclusively in R5 C-HIV V3Figure 3 A diagrammatic representation of the CoRSeqV3-C algorithm
subjected to a sequential series of questions, which are ordered from top t
Results section.sequences (Table 1), namely Glu10, Glu23 or a gap at
position 23. If one or more of these amino acid alterations
are present, the query sequence is determined to be that of
a R5 C-HIV Env. If not, the query sequence is assessed for
the presence of a number of signature CXCR4-using
C-HIV V3 sequence characteristics and amino acid
alterations that either (i) occur exclusively in CXCR4-
using C-HIV V3 sequences, (ii) occur significantly more
frequently in CXCR4-using C-HIV V3 sequences than in
R5 C-HIV V3 sequences (Table 1), or (iii) improve the sen-
sitivity and/or specificity of the algorithm for detecting
CXCR4-using C-HIV variants (Additional file 1). Specific-
ally, these CXCR4-using C-HIV signature alterations
include an amino acid substitution within the GPGQ V3
crown motif and/or an immediately proximal two amino
acid insertion, a net V3 amino acid charge of ≥6, and the
presence of Lys11, Arg11, His11, Ile11, Asn11, Arg25,
His25, Lys25, Thr25, a gap at position 25 or Phe34. If any. Query V3 sequences are aligned to the HXB2 V3 sequence and
o bottom as indicated by arrows, and as described in detail in the
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to be that of a CXCR4-using C-HIV Env.
Performance of CoRSeqV3-C compared to other V3-based
coreceptor usage prediction algorithms and tools
We next assessed the accuracy of CoRSeqV3-C for
predicting C-HIV coreceptor usage compared to several
other prediction rules and algorithms (Table 2). We used
two C-HIV V3 sequence data sets. Data set 1 was
restricted to one representative V3 sequence per subject
(69 CXCR4-using and 473 R5 Envs). Because CoRSeqV3-C
was developed using the V3 sequences of data set 1, we
would anticipate a high sensitivity and specificity for our
algorithm. Thus, we included a second data set in the
study (data set 2), which consisted of every phenotypically
characterized C-HIV V3 sequence currently available,
allowing multiple sequences per patient (143 CXCR4-
using and 1213 R5 C-HIV Envs). The other coreceptor
usage prediction algorithms assessed were the
Geno2pheno[coreceptor] algorithm [36], the C-HIV specific
WebPSSM algorithm (WebPSSMSINSI-C), two different B-
HIV specific WebPSSM algorithms (WebPSSMx4r5-B and
WebPSSMSINSI-B) [24,37], the 11/25 rule [25,38], the
11/24/25 rule [22,25,39,40], the 11/25/V3 charge rule
[27], and the Lin et al., rule [41]. These rules and
algorithms are described in the methods.
We found the 11/25 rule to be the least sensitive at
correctly predicting CXCR4 usage in both data sets, with
sensitivities of 46.38% and 47.87% for data sets 1 and 2,
respectively (Table 2). Notably, the 11/24/25 rule showed
comparatively improved sensitivity, with 56.52% and
52.12% for data sets 1 and 2, respectively. The 11/25/V3
charge rule showed further improvement, with 79.71%
and 77.47% sensitivity for data sets 1 and 2, respectively.
The Lin et al. rule had 84.06% and 79.58% sensitivity for
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11/25/V3 charge 79.71 88.16
Lin et al. rule 84.06 96.83Among the more sophisticated V3 algorithms,
Geno2pheno[coreceptor] and WebPSSMSINSI-C both had
sensitivities of 88.41% for data set 1, and sensitivities of
87.32% and 88.02% for data set 2, respectively.
Geno2pheno[coreceptor] was 94.71% specific for data set 1
and 99.96% specific for data set 2. WebPSSMSINSI-C
was 90.7% specific for data set 1 and 99.86% specific
for data set 2. The B-HIV specific WebPSSMx4r5-B
and WebPSSMSINSI-B algorithms were comparatively
inaccurate for C-HIV sequences, showing 78.26% and
59.42% sensitivities for data set 1, and 69.72% and
57.04% sensitivities for data set 2, respectively. In
comparison, CoRSeqV3-C was 94.2% sensitive and
91.12% specific for data set 1, and 90.85% sensitive
and 99.98% specific for data set 2. Interestingly, the
same CXCR4-using V3 sequences from data set 1
(n=4) and data set 2 (n=5) were incorrectly scored as
R5 by all of the algorithms and rules investigated in
this study, further highlighting that regions outside the V3
loop can confer CXCR4 usage, albeit in a minority of
sequences. Together, our results show that CoRSeqV3-C
has superior sensitivity for detection of C-HIV CXCR4
usage compared to the best performing alternative
algorithms, with comparable specificity.
Discussion
In this study we conducted an extensive and compre-
hensive analysis of CXCR4-using and R5 C-HIV Envs in
order to develop a novel C-HIV specific coreceptor
usage prediction algorithm that is highly sensitive at
predicting C-HIV CXCR4-usage. To do this we
assembled every phenotypically characterized C-HIV
Env V3 sequence available on the Los Alamos HIV Data-
base and elucidated the specific sequence characteristics
of V3 that differentiate R5 from CXCR4-using Envs. We
found that CXCR4-using C-HIV V3 sequences have aative algorithms and tools for predicting C-HIV coreceptor
ct All C-HIV V3 sequences
R5) (Data set 2; 143 CXCR4-using and 1213 R5)
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R5 Envs, consistent with the results of previous studies
[22,23,29,41,42]. Crystal structure analysis and mutagen-
esis studies have shown that the V3 loop interacts
directly with the coreceptor N-terminus and ECL2
region [43-45]. The surface of CXCR4 is more negatively
charged than CCR5. Thus, Envs with a more positively
charged V3 may have an enhanced interaction with
CXCR4. We also found that CXCR4-using Envs are
significantly less likely to have a PNGS within V3
than R5 Envs. Previous studies have suggested that
the V3 N-terminal glycan enhances the interaction of
gp120 with CCR5 [46-48]. Conversely, loss of this glycan
has been shown to enhance viral CXCR4 usage [47,49].
Analysis of the amino acid type and frequency within V3,
comparing R5 and CXCR4-using C-HIV Envs, revealed that
CXCR4-using Envs have greater V3 variability than R5
Envs, consistent with previous studies [23,42]. Interestingly,
the majority of CXCR4-using C-HIV Envs had either an
amino acid substitution within the V3 GPGQ crown motif
and/or a two amino acid substitution immediately proximal
to the crown motif. The association between CXCR4-usage
and a V3 crown motif alteration has been discussed in
previous studies [27,29,41,42]. The V3 crown forms a beta
turn secondary structure at the tip of the V3 loop. Recently,
we constructed three-dimensional homology models of a
primary X4 C-HIV gp120 with a GRGQ V3 crown motif
and/or an Ile314-Gly315 insertion (M.R. Jakobsen, K .
Cashin and P.R. Gorry, unpublished data), and showed that
these alterations may potentially cause significant confor-
mational changes in V3, which may enhance V3 flexibility
and thus the interaction with CXCR4. V3 crown alterations
and two amino acid insertions immediately proximal to the
V3 crown occur more frequently in C-HIV CXCR4-using
Envs than in any other HIV-1 subtype. However, ana-
lysis of 151 phenotypically characterized CXCR4-using
and 225 R5 B-HIV V3 sequences obtained from the
Los Alamos HIV database (one sequence per subject)
revealed that a greater proportion of CXCR4-using B-HIV
Envs have a two amino acid insertion (10%) immediately
proximal to the V3 crown than R5 B-HIV Envs (0%).
Therefore, although this two amino acid insertion occurs
significantly less frequently in B-HIV CXCR4-using
Envs than C-HIV CXCR4-using Envs (p<0.0001 by
Fisher’s exact test), this defining characteristic of
CXCR4-usage may therefore not be unique to C-HIV
Envs. The presence of a V3 crown alteration was not
significantly different between R5 (28%) and CXCR4-
using (30%) B-HIV Envs.
We identified sequence characteristics in regions out-
side of V3 that are associated with coreceptor specificity,
specifically in the V1 and V4 loops. Previous studies
have described associations between sequence alterations
within the V1/V2 loops and C-HIV coreceptor usage[32,50]. However, we recently showed that a V1 swap
from a primary R5 C-HIV Env into an X4 C-HIV Env
which developed in the same subject did not affect
coreceptor usage, despite distinct sequence alterations in
V1 segregating these two Envs (M.R. Jakobsen, K. Cashin
and P.R. Gorry, unpublished data). Previous studies have
suggested that extensive V1/V2 sequence mutations need
to occur prior to the V3 mutations that are critical for
CXCR4-usage of C-HIV [50,51]. Thus, the V1 swap experi-
ment may have shown no affect on coreceptor usage
because the V3 mutations necessary for CXCR4-usage were
already present. Due to the limited number of pheno-
typically characterized full-length CXCR4-using C-HIV
sequences, we did not conduct an amino acid type and
frequency analysis outside the V3 region. However,
Dimonte et al. [29] have conducted such a study,
using C-HIV sequences predicted to use CXCR4 by
Geno2pheno[coreceptor], WebPSSMSINSI-C and 11/25/V3
charge. Here, the investigators identified multiple
amino acids within gp41 that could be used to
differentiate R5 from CXCR4-using C-HIV Envs,
suggesting their inclusion in a coreceptor specificity
prediction algorithm could improve predictive accu-
racy. However, a study by Thielen et al. [52] suggests that
the inclusion of gp41 mutations does not substantially
improve predictive accuracy.
A study by Raymond et al. [27] found the 11/25/V3
charge rule to be more accurate than the 11/25 rule,
Geno2pheno[coreceptor] and WebPSSMSINSI-C algorithms
for predicting coreceptor specificity. While we found
the 11/25/V3 charge rule to be more accurate than
the 11/25 rule and the 11/24/25 rule, it was less accurate
than Geno2pheno[coreceptor], WebPSSMSINSI-C, CoRSeqV3-C
and the HIV-B specific WebPSSMx4r5-B algorithms. A
recent study, by Lin et al. [41], utilizing 209 sequences
isolated from 16 C-HIV infected subjects, also identified
the association between C-HIV CXCR4 usage and a
V3 crown alteration and/or a two amino acid inser-
tion proximal to the V3 crown. Exploiting these V3
characteristics, the investigators were able to correctly
predict 100% of the X4 Envs, 76.9% of the R5X4 Envs
and 100% of the R5 Envs studied [41]. In our analysis,
we found the Lin et al. rule to be more accurate than the
11/25 rule, the 11/24/25 rule, the 11/25/V3 charge rule
and the HIV-B specific WebPSSM algorithms at
predicting HIV-C CXCR4 usage. However, the Lin et al.
rule was less accurate than the Geno2pheno[coreceptor],
WebPSSMSINSI-C, or CoRSeqV3-C algorithms.
We developed CoRSeqV3-C by determining the combi-
nation of V3 characteristics and amino acids specific to R5
or CXCR4-using C-HIV Envs that most accurately predict
the coreceptor usage of all the currently available pheno-
typically characterized C-HIV V3 sequences. Future
performance evaluation with additional phenotypically
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to more completely evaluate the sensitivity and specificity
of CoRSeqV3-C, which will be conducted as more C-HIV
V3 sequences are deposited into the Los Alamos HIV
database. We showed that CoRSeqV3-C was maximally
sensitive and specific for predicting CXCR4 usage when
data was restricted to just one representative se-
quence per patient, which is a desirable quality. Im-
portantly, as more C-HIV V3 sequences become
available, CoRSeqV3-C can be reviewed for the potential
inclusion of other V3 characteristics and/or amino acids
in order to further maximize its sensitivity and specificity.
Thus, unlike previously developed algorithms, CoRSeqV3-
C is adaptable. CXCR4-using C-HIV Envs were first
reported in patients on ART, and studies have
suggested that ART provides a selective environment
that may drive the emergence of CXCR4-using variants
[53]. Thus, as ART become more widely available in
C-HIV affected areas, adaptability may be an import-
ant quality for a C-HIV specific coreceptor specificity
prediction algorithm.
Conclusions
In summary, this study has advanced the genotypic
characterization of C-HIV coreceptor usage. We elucidated
the specific V3 sequence alterations associated with
CXCR4-usage of C-HIV, and utilized these findings to
develop an improved C-HIV specific V3 based coreceptor
usage prediction algorithm. By comparison to the alterna-
tive predictive rules and algorithms, using two data sets that
together comprise every available C-HIV V3 sequence, we
have determined that CoRSeqV3-C is presently the most
sensitive algorithm for predicting CXCR4 usage of
C-HIV, with specificity that remains comparable to
the best performing alternative algorithms. Not only
does CoRSeqV3-C have the potential to be a useful
tool for assisting clinicians to decide the best treat-
ment options for patients with C-HIV infection, this
new algorithm builds capacity for future studies of
C-HIV pathogenesis.
Methods
C-HIV V3 sequence data sets
For this study we combined all phenotypically cha-
racterized C-HIV V3 sequences currently available in the
Los Alamos Database (as of December 2012; n=1056),
which were derived from diverse geographical locations
such as Africa, India, South America, Europe, Israel and
China with sequences from a longitudinal C-HIV
study that we recently conducted (n=300) (M.R.
Jakobsen, K. Cashin and P.R. Gorry, unpublished
data). V3 sequences from Envs that were determined
to use CXCR4 in cell entry assays or cause syncytia
in MT-2 cells were labeled “CXCR4-using” sequences(n=143). V3 sequences from Envs that were deter-
mined to use CCR5 only in cell entry assays or did
not induce syncytia in MT-2 cells were labeled “R5”
sequences (n=1213).Coreceptor usage prediction rules and algorithms
The in silico algorithms assessed in this study were
Geno2pheno[coreceptor] using a false-positive rate of 10%
(http://coreceptor.bioinf.mpi-inf.mpg.de/), as well as the
C-HIV and B-HIV specific WebPSSM algorithms (http://
indra.mullins.microbiol.washington.edu/webpssm/). The
11/25 rule predicts CXCR4-usage based on the presence
of Arg, Lys or His at position 11 and/or 25 within the
V3 region of gp120 [25,38]. The 11/24/25 rule predicts
CXCR4-usage based on the presence of Arg, Lys or His
at position 11, 24 and/or 25 within the gp120 V3
sequence [22,25,39,40]. The 11/25/V3 charge rule [27]
predicts CXCR4-usage based on three criteria; (i) Arg/
Lys at position 11 and/or Lys at position 25, (ii) Arg at
position 25 and a net charge of ≥5, or (iii) a net charge
of ≥6. The Lin et al. rule [41] predicts CXCR4-usage
based on the presence of an alteration within the V3
GPGQ crown motif and/or the presence of a two amino
acid insertion immediately proximal to the V3 crown, at
positions 13 and 14. V3 net charge was calculated by
subtracting the number of negatively charge amino acids
(Asp and Glu) from the number of positively charged
amino acids (Lys, Arg and His). Sensitivities were
calculated by dividing the total number of correctly
predicted CXCR4-using sequences by the total
number of phenotypically characterised CXCR4-using
sequences, and multiplying this number by 100.
Specificities were calculated by dividing the number
of correctly predicted R5 sequences by the total
number of phenotypically characterised R5 sequences,
and multiplying this number by 100.Sequence analyses
Sequence alignments were developed using CLC Main
Workbench version 6.5. Sequence variability at each
amino acid position was determined using the Los
Alamos Database Entropy-One tool (http://www.hiv.
lanl.gov/content/sequence/ENTROPY/entropy.html).
Potential N-linked glycosylation sites were predicted using
the Los Alamos Database N-Glycosite tool (http://www.hiv.
lanl.gov/content/sequence/GLYCOSITE/glycosite.html).Statistical analysis
P-values were calculated using either a Fisher’s Exact test
or a Mann Whitney U test. Values <0.05 were considered
significant. All statistical tests were performed using Prism
version 5.0 (GraphPad Software Inc., San Diego, CA).
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